Market Intelligence, Clinical Progress, and High-Purity Reagents for Antiviral and Cancer Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for DDX58/RIG-I drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Full-Length) | DDX58 Full-Length Recombinant Protein, high purity (>95%), Endotoxin <1EU/ug. Sequence Verified. | View DDX58 Products |
| Antigen (Helicase Domain) | DDX58 Helicase Domain Recombinant Protein (aa 227-925), ATP-binding site intact, Endotoxin <1EU/ug. | View DDX58 Products |
| Antigen (CARD Domain) | DDX58 N-terminal CARD Domains (1-228aa), for MAVS interaction studies. Theoretical MW verified. | View DDX58 Products |
| Mutant Control | DDX58 K270A Helicase Mutant (ATPase-deficient negative control), HEK293 expressed. | View DDX58 Products |
| Gene Delivery | DDX58 Promise-ORF / Lentivirus (full-length ORF for stable cell lines). | View DDX58 Products |
| Benchmark Ab | Anti-DDX58 Antibody (recombinant positive control for western blot and ELISA). | View DDX58 Products |
| Validator | DDX58 siRNA Set (for knockdown verification). | View DDX58 Products |
| Pathway Partner | MAVS CARD Domain Protein (downstream adaptor for CARD-CARD interaction assays). | View MAVS Products |
| Parallel Sensor | IFIH1 (MDA5) Helicase Domain (orthologous RNA sensor for selectivity screening). | View IFIH1 Products |
| Downstream Node | STING1 (TMEM173) Full Length & Ligand Binding Domain (for pathway crosstalk studies). | View STING1 Products |
| Regulatory Factor | DHX58 (LGP2) Helicase Domain (RIG-I regulator/competitor for mechanistic studies). | View DHX58 Products |
Critical Assay Challenges and TarMart Advantages
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| False Pathway Activation by Contaminants | Endotoxin Controlled (<1EU/ug) and High Purity (>95%) for sensitive immune assays |
| ATPase Activity Screening | Wild-type DDX58 helicase domain with intact Walker A/B motifs; K270A mutant available as negative control (>95% purity, mass spec verified) |
| CARD-CARD Interaction (MAVS Binding) | Soluble CARD domain constructs (1-228aa) avoiding aggregation; compatible with AlphaScreen/SPR |
| Selectivity vs. MDA5 (IFIH1) | Human MDA5 helicase domain strictly purified under identical conditions for pairwise comparison |
| RNA Ligand Competition | High-concentration protein stocks (mg/mL scale) for biophysical RNA binding assays |
Live DDX58/RIG-I R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for DDX58/RIG-I therapeutics is intensifying. Major players are shifting focus from traditional antivirals to innate immune agonists for oncology, driven by the success of immune checkpoint inhibitors. First-generation pan-viral mimics face tolerability challenges, so the next wave of R&D is targeting selective helicase-domain activators for solid tumor immunotherapy (converting immunologically "cold" tumors to "hot" tumors) and CARD-domain inhibitors for autoimmune indications such as systemic lupus and Sjögren's syndrome. Concurrently, the field is moving beyond broad STING agonists toward fine-tuned RIG-I/MDA5 pathway modulation, with combination therapy (RIG-I agonist + PD-1/PD-L1 inhibitor) being a pivotal strategy.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Agonist | Merck, Spring Discovery, Curadev | Solid Tumors (Immuno-oncology) | ATPase Activity Assay (need active helicase domain with Walker motifs) |
| Small Molecule Antagonist | Biogen, Novartis | Lupus, Sjögren's (Autoimmune) | MAVS Interaction Blockade (CARD-CARD binding assays) |
| RNA Mimetics/Therapeutics | BioNTech, Multiple Academic Groups | Solid Tumors, Viral Infections, HBV | Binding Assays (high-purity RNPs); RNA-Protein Binding |
| Gene Therapy | Academic/Startups, Kinnate | Refractory Cancers | Cell Line Construction (ORF/Lentivirus) |
| Biologics (Intracellular) | Cell Penetrant Peptide Conjugates | Refractory Tumors | Intracellular Stability (full-length protein standards) |
Key Functional Domains and Mutations
DDX58 (RIG-I) contains three major functional domains: CARD 1 and CARD 2 (N-terminal, residues 1-228) mediate interaction with MAVS; the Helicase ATP-binding domain (central region) harbors conserved Walker A/B motifs critical for ATP hydrolysis and RNA unwinding. Clinically relevant mutations include dbSNP:rs10813831 (sequence variant) and two SGMRT2-associated mutations (VAR_073667, VAR_073668) that cause constitutive activation, leading to enhanced interferon signaling. TarMart provides wild-type and mutant (e.g., K270A) recombinant proteins to support mechanism-of-action and drug resistance studies.